Immunotherapy clinical trial assesses opportunity to prevent lung cancer development, recurrence
An immunotherapy used against advanced non-small cell lung cancer is being tested at MD Anderson for a different job: preventing the disease from developing in people with pre-cancerous lung nodules.
The first-of-its-kind Phase II clinical trial is based on research into these precancerous growths by Jianjun Zhang, M.D., Ph.D., assistant professor of Thoracic/Head and Neck Medical Oncology.
How...
Metastatic cells, mechanisms of drug resistance identified for triple-negative breast cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered important mechanisms of drug resistance and metastasis in...
Combination therapy key in two studies of blood cancers likely to relapse
Results from two MD Anderson studies demonstrated the significance of combination therapy in follicular lymphoma and chronic lymphoblastic...
Immunotherapy innovation: Moon Shots effort aims natural killer cells at cancer
MD Anderson’s adoptive cell therapy (ACT) platform is advancing the next generation of cell-based immune therapies to bring innovative approaches to our patients quickly, safely and effectively. The platform is one of the research engines driving MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.
By working closely...
